Skip to main content

Market Overview

Voyager Therapeutics' Vectorized Anti-Tau Antibody Shows Encouraging Preclinical Data In CNS Disorders

Voyager Therapeutics' Vectorized Anti-Tau Antibody Shows Encouraging Preclinical Data In CNS Disorders
  • Voyager Therapeutics Inc (NASDAQ: VYGR) has announced new preclinical data characterizing the durable expression and activity of a vectorized anti-tau antibody.
  • The results will be presented at the American Society of Gene and Cell Therapy.
  • Data demonstrate durable expression in the central nervous system (CNS). They may represent a new single-dose therapeutic strategy for treating various tauopathies such as progressive supranuclear palsy, frontal, temporal dementia, and Alzheimer's disease.
  • Voyager has developed modular antibody vectorization cassettes consisting of an adeno-associated virus (AAV) vector and a transgene encoding anti-tau monoclonal full-length antibodies.
  • Following intravenous administration and transduction of target cells in the brain, the expressed antibodies are functionally reconstituted and subsequentially secreted into the parenchyma.
  • Anti-tau antibody expression was detected as early as two days post-dose, reaching maximum levels at day 7, with durable expression extending to 28 days.
  • Dose-dependent decreases in the levels of pathological tau and neurofibrillary tangles were observed, resulting in up to 59% reduction in tau pathology.
  • Price Action: VYGR shares are trading 2.5% higher at $4.51 on the last check Wednesday.

Related Articles (VYGR)

View Comments and Join the Discussion!

Posted-In: Alzheimer's disease central nervous system disordersBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at